Sprint Bioscience Ab Stock Retained Earnings
SPRINT Stock | SEK 1.82 0.02 1.09% |
Sprint Bioscience AB fundamentals help investors to digest information that contributes to Sprint Bioscience's financial success or failures. It also enables traders to predict the movement of Sprint Stock. The fundamental analysis module provides a way to measure Sprint Bioscience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sprint Bioscience stock.
Sprint |
Sprint Bioscience AB Company Retained Earnings Analysis
Sprint Bioscience's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Sprint Bioscience Retained Earnings | (39 M) |
Most of Sprint Bioscience's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sprint Bioscience AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
Competition |
Based on the latest financial disclosure, Sprint Bioscience AB has a Retained Earnings of (39 Million). This is 104.19% lower than that of the Healthcare sector and 171.86% lower than that of the Drug Manufacturers - Specialty & Generic industry. The retained earnings for all Sweden stocks is 100.42% higher than that of the company.
Did you try this?
Run Performance Analysis Now
Performance AnalysisCheck effects of mean-variance optimization against your current asset allocation |
All Next | Launch Module |
Sprint Fundamentals
Return On Equity | -1.09 | |||
Return On Asset | -0.59 | |||
Operating Margin | (76.00) % | |||
Current Valuation | 24.98 M | |||
Shares Outstanding | 69.8 M | |||
Shares Owned By Insiders | 35.31 % | |||
Shares Owned By Institutions | 2.59 % | |||
Price To Earning | 32.79 X | |||
Price To Book | 2.61 X | |||
Price To Sales | 27.09 X | |||
Revenue | 35.11 M | |||
Gross Profit | 24.59 M | |||
EBITDA | (24.22 M) | |||
Net Income | (25.08 M) | |||
Cash And Equivalents | 13.82 M | |||
Cash Per Share | 1.19 X | |||
Debt To Equity | 32.20 % | |||
Current Ratio | 2.69 X | |||
Book Value Per Share | 0.63 X | |||
Cash Flow From Operations | (40.12 M) | |||
Earnings Per Share | (0.75) X | |||
Target Price | 32.0 | |||
Number Of Employees | 34 | |||
Beta | 1.32 | |||
Market Capitalization | 53.17 M | |||
Total Asset | 79.14 M | |||
Retained Earnings | (39 M) | |||
Working Capital | 4 M | |||
Current Asset | 25 M | |||
Current Liabilities | 21 M | |||
Net Asset | 79.14 M |
About Sprint Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sprint Bioscience AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sprint Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sprint Bioscience AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Sprint Stock
Sprint Bioscience financial ratios help investors to determine whether Sprint Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sprint with respect to the benefits of owning Sprint Bioscience security.